Dados do Trabalhos de Conclusão

UNIVERSIDADE FEDERAL DA BAHIA
CIÊNCIA ANIMAL NOS TRÓPICOS (28001010036P7)
FARMACOCINÉTICA DO ALOPURINOL EM CÃES SOB TRATAMENTO PARA LEISHMANIOSE VISCERAL NATURALMENTE ADQUIRIDA
CLAUCEANE DE JESUS
DISSERTAÇÃO
10/03/2017

TrataTrata Trata -se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em se de um estudo clínico prospectivo sobre a farmacocinética do alopurinol em cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por cães naturalmente infectados por LeishmaniaLeishmaniaLeishmania Leishmania infantum infantum e domiciliados com seus e domiciliados com seus e domiciliados com seus e domiciliados com seus e domiciliados com seus e domiciliados com seus e domiciliados com seus e domiciliados com seus e domiciliados com seus e domiciliados com seus responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV).responsáveis em área endêmica para leishmaniose visceral (LV). responsáveis em área endêmica para leishmaniose visceral (LV). O objetivo do estudo O objetivo do estudo O objetivo do estudo O objetivo do estudo O objetivo do estudo O objetivo do estudo O objetivo do estudo foi deter deter min ar os parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol e os parâmetros farmacocinéticos do alopurinol eos parâmetros farmacocinéticos do alopurinol e seu metabólitoseu metabólitoseu metabólito seu metabólito seu metabólito seu metabólito oxipurinol em cães oxipurinol em cães oxipurinol em cães oxipurinol em cães oxipurinol em cães oxipurinol em cães oxipurinol em cães oxipurinol em cães oxipurinol em cães em em tratamento para tratamento para tratamento para tratamento para tratamento para tratamento para tratamento para LV caninaLV caninaLV caninaLV caninaLV caninaLV canina . Para ara ara tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, tanto, foram avaliados 11 cães, que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinéticaque passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética que passaram por avaliação clínica e laboratorial. Para o estudo da farmacocinética , foram coletadas a foram coletadas aforam coletadas a foram coletadas aforam coletadas a foram coletadas aforam coletadas aforam coletadas a foram coletadas amostras mostras mostras de sangue de sanguede sangue de sangue de sangue de cada cão de cada cão de cada cão de cada cão de cada cão de cada cão de cada cão de cada cão de cada cão de cada cão de cada cão de cada cão antes e antes e antes e antes e 12h após a administração do após a administração do após a administração do após a administração do após a administração do após a administração do após a administração do após a administração do após a administração do após a administração do após a administração do após a administração do alopurinolalopurinol , por via oral por via oral por via oralpor via oral por via oral, na dose de 10mg/kg, nos tempos na dose de 10mg/kg, nos temposna dose de 10mg/kg, nos tempos na dose de 10mg/kg, nos temposna dose de 10mg/kg, nos temposna dose de 10mg/kg, nos temposna dose de 10mg/kg, nos temposna dose de 10mg/kg, nos tempos na dose de 10mg/kg, nos temposna dose de 10mg/kg, nos tempos na dose de 10mg/kg, nos temposna dose de 10mg/kg, nos tempos na dose de 10mg/kg, nos tempos na dose de 10mg/kg, nos temposna dose de 10mg/kg, nos tempos 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 0’ 15’, 30’,1; 1,5; 2; 2,5; 3; 4; 5; 7; 10; 12 h 5; 7; 10; 12 h 5; 7; 10; 12 h 5; 7; 10; 12 h 5; 7; 10; 12 h. Amostra mostra s de urina de urina de urina de urina foram foram foram coletacoleta da s nos tempos 0 nos tempos 0 nos tempos 0-3 h; 3 h; 3 h; 3-6 h; 6 h; 6 h; 6-9 h; 10 9 h; 10 9 h; 10 -12 horas oras após após administração do fármacoadministração do fármaco administração do fármaco administração do fármaco administração do fármacoadministração do fármacoadministração do fármaco administração do fármaco administração do fármaco administração do fármaco administração do fármacoadministração do fármaco. Na avaliação clínica Na avaliação clínicaNa avaliação clínicaNa avaliação clínica Na avaliação clínica Na avaliação clínicaNa avaliação clínicaNa avaliação clínicaNa avaliação clínica Na avaliação clínicaNa avaliação clínica Na avaliação clínica dos cães dos cãesdos cãesdos cãesdos cães, os sinaisos sinais os sinais mais mais mais frequentes frequentes frequentes frequentes frequentes frequentes foram foram foram linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraç linfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alteraçlinfadenomegalia, mucosas hipocaradas e alterações ões dermatológicadermatológicadermatológica dermatológica dermatológica dermatológica dermatológicas. Na análise dos exames laboratoriais Na análise dos exames laboratoriaisNa análise dos exames laboratoriaisNa análise dos exames laboratoriais Na análise dos exames laboratoriais Na análise dos exames laboratoriais Na análise dos exames laboratoriaisNa análise dos exames laboratoriais Na análise dos exames laboratoriaisNa análise dos exames laboratoriaisNa análise dos exames laboratoriaisNa análise dos exames laboratoriaisNa análise dos exames laboratoriais Na análise dos exames laboratoriais Na análise dos exames laboratoriaisNa análise dos exames laboratoriais Na análise dos exames laboratoriais , observou observouobservou -se anemia emanemia emanemia emanemia em anemia emanemia emanemia emanemia em 18,2 % (2/11 (2/11(2/11) dos cães, dos cães, dos cães, dos cães, dos cães, dos cães, hiperprotei hiperprotei hiperproteinemia e nemia e nemia enemia enemia em 45 ,4% (5 /11) /11) , hiperglobulinemia , hiperglobulinemia , hiperglobulinemia, hiperglobulinemia, hiperglobulinemia, hiperglobulinemia , hiperglobulinemia em em 81,8 % (9 /11), /11), hipoalbuminemia em hipoalbuminemia em hipoalbuminemia em hipoalbuminemia em hipoalbuminemia em hipoalbuminemia em hipoalbuminemia em 81,8% 81,8% (9/11), (9/11), e níveis elevados de ALT em níveis elevados de ALT emníveis elevados de ALT em níveis elevados de ALT em níveis elevados de ALT em níveis elevados de ALT emníveis elevados de ALT emníveis elevados de ALT emníveis elevados de ALT emníveis elevados de ALT emníveis elevados de ALT emníveis elevados de ALT em 18,2% (2/11 18,2% (2/1118,2% (2/11 18,2% (2/11 18,2% (2/11) e FA emFA emFA emFA emFA em 18,2% (2/11 (2/11) dos cães. cães. cães. cães. A razão proteína razão proteínarazão proteínarazão proteína razão proteína razão proteína -creatinina urinária (creatinina urinária (creatinina urinária (creatinina urinária (creatinina urinária ( creatinina urinária ( creatinina urinária ( creatinina urinária ( creatinina urinária (creatinina urinária (UPC ) estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em estava alterada em 36,4 % (4 /11) /11) dos cães, porém dos cães, porém dos cães, porém dos cães, porém dos cães, porém dos cães, porém dos cães, porém dos cães, porém dois tinh tinh am vaam va am va lores limítrofe lores limítrofe lores limítrofe lores limítrofe lores limítrofe lores limítrofes e cincoe cincoe cincoe cinco e cincoe cinco dentro d dentro d dentro da normalidade normalidade normalidade normalidade . Na urinálise . Na urinálise. Na urinálise. Na urinálise. Na urinálise . Na urinálise . Na urinálise , observ observ ou -se proteinúria em proteinúria em proteinúria em proteinúria em proteinúria em proteinúria em 63,6% 63,6% (7/11), (7/11), hematúrihematúrihematúri hematúria em a em a em a em a em 9,1% (1/11) (1/11) , leucocitúria em leucocitúria emleucocitúria emleucocitúria em leucocitúria em leucocitúria emleucocitúria emleucocitúria emleucocitúria em 27 ,3% (3 /11) /11) , bacteriúria em , bacteriúria em , bacteriúria em , bacteriúria em , bacteriúria em , bacteriúria em , bacteriúria em , bacteriúria em , bacteriúria em 63,6 % (7 /11) /11)/11), cristais de cristais de cristais de cristais de cristais de urato de amônio em urato de amônio em urato de amônio em urato de amônio emurato de amônio emurato de amônio em urato de amônio em urato de amônio emurato de amônio em 9,1% 9,1% (1/11) (1/11) , cristais , cristais , cristais , cristais de urato de urato de urato de urato de urato amorfos morfos 9,1% 9,1% (1/11) (1/11)(1/11) e cristais de e cristais de e cristais de e cristais de e cristais de e cristais de e cristais de xantina emxantina emxantina em xantina em xantina emxantina emxantina em 9,1% (1/11) (1/11) dos cães . Os resultados da análise de patologia clínica foram Os resultados da análise de patologia clínica foram

farmacocinética;alopurinol;leishmaniose visceral
This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs This is a prospective clinical study of the pharmacokinetics allopurinol in dogs naturally infected by naturally infected by naturally infected by naturally infected by naturally infected by naturally infected by naturally infected by naturally infected by naturally infected by naturally infected by naturally infected by naturally infected by Leishmania spLeishmania spLeishmania sp Leishmania sp Leishmania sp . and domiciled . and domiciled . and domiciled . and domiciled . and domiciled . and domiciled . and domiciled . and domiciled with their guardians with their guardians with their guardianswith their guardianswith their guardians with their guardians with their guardians in in an an endemic endemic endemic endemic endemic area for visceral area for visceral area for visceral area for visceral area for visceral area for visceral area for visceral area for visceral area for visceral area for visceral area for visceral area for visceral leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine leishmaniasis (VL). The aim of the study was to determine pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in pharmacokinetic parameters of allopurinol and its metabolite oxypurinol in dogs dogs undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. undergoing treatment for canine visceral leishmaniasis. We evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that e evaluated 11 dogs that underwent clinical and laborator underwent clinical and laborator underwent clinical and laboratorunderwent clinical and laborator underwent clinical and laboratorunderwent clinical and laborator underwent clinical and laborator underwent clinical and laborator underwent clinical and laboratorunderwent clinical and laborator underwent clinical and laborator underwent clinical and laboratorunderwent clinical and laborator y evaluation. y evaluation. y evaluation. y evaluation. y evaluation. y evaluation. For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood For the pharmacokinetic study, blood samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of samples from each dog were collected before and 12 hours after the administration of allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; allopurinol, orally, at a dose of 10mg / kg, times 0 '15', 30 ', 1; 1.5; 2; 2.5; 3; 4; 5; 7; 10; 12 h. 10; 12 h. 10; 12 h. Urine samples Urine samples Urine samples Urine samples Urine samples Urine samples were collected at 0 were collected at 0 were collected at 0were collected at 0were collected at 0 were collected at 0were collected at 0were collected at 0 were collected at 0were collected at 0 were collected at 0-3 h; 3 h; 3 h; 3-6 h; 6 h; 6 h; 6-9 h; 10 9 h; 10 9 h; 10 -12 h 12 hours after after after the drug drug drug drug administration.administration. administration. administration. administration. administration. The most frequent signs he most frequent signs he most frequent signs he most frequent signs he most frequent signs he most frequent signs he most frequent signs he most frequent signs he most frequent signs he most frequent signs he most frequent signs observed i observed i observed iobserved iobserved iobserved in the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs n the clinical evaluation of dogs were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, were lymphadenomegaly, pale pale mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. mucosa and dermatological alterations. Laboratory testsaboratory testsaboratory tests aboratory tests aboratory testsaboratory testsaboratory tests evidenced evidenced evidenced evidenced anemia ianemia ianemia ianemia i anemia ianemia ianemia in 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), n 18.2% (2/11) of the dogs, hyperproteinemia in 45.4% 5/11), hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT hyperglobulinemia in 81.8% (9/11), hypoalbuminemia elevated ALT levels in 18.2% (2/11), levels in 18.2% (2/11), levels in 18.2% (2/11), levels in 18.2% (2/11), levels in 18.2% (2/11), levels in 18.2% (2/11), levels in 18.2% (2/11), levels in 18.2% (2/11), and and high FA high FA high FA high FA high FA high FA values values values in 18.2% (2/11) of in 18.2% (2/11) of in 18.2% (2/11) of in 18.2% (2/11) of in 18.2% (2/11) of in 18.2% (2/11) of in 18.2% (2/11) of in 18.2% (2/11) of in 18.2% (2/11) of the dogs. dogs. dogs. dogs. The urinary The urinary The urinary The urinary The urinary The urinary protein protein -creatinine ratio (UPCcreatinine ratio (UPCcreatinine ratio (UPCcreatinine ratio (UPCcreatinine ratio (UPC creatinine ratio (UPC creatinine ratio (UPC creatinine ratio (UPC creatinine ratio (UPC creatinine ratio (UPC creatinine ratio (UPCcreatinine ratio (UPC) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had ) was altered in 36.4% (4/11) of the dogs, two had borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value.borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value.borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value.borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. borderline values and five results within the normal value. The urinalysis he urinalysishe urinalysis he urinalysishe urinalysishe urinalysishe urinalysis resulted in resulted in resulted in resulted in resulted in resulted in proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/proteinuria in 63.6% (7/11), hematuria 9.1% 1/leukocyturia 27.3% 3/bacteriuria in 63.6% (7/11), ammo bacteriuria in 63.6% (7/11), ammobacteriuria in 63.6% (7/11), ammo bacteriuria in 63.6% (7/11), ammo bacteriuria in 63.6% (7/11), ammobacteriuria in 63.6% (7/11), ammobacteriuria in 63.6% (7/11), ammo bacteriuria in 63.6% (7/11), ammo bacteriuria in 63.6% (7/11), ammobacteriuria in 63.6% (7/11), ammobacteriuria in 63.6% (7/11), ammo bacteriuria in 63.6% (7/11), ammo bacteriuria in 63.6% (7/11), ammobacteriuria in 63.6% (7/11), ammo bacteriuria in 63.6% (7/11), ammonium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous nium urate crystals in 9.1% (1/11), amorphous crystals 9.1% (1/11)crystals 9.1% (1/11)crystals 9.1% (1/11)crystals 9.1% (1/11) crystals 9.1% (1/11) crystals 9.1% (1/11)crystals 9.1% (1/11) crystals 9.1% (1/11) , and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs. and xanthine crystals in 9.1% (1/11) of the dogs.and xanthine crystals in 9.1% (1/11) of the dogs. The results of the The results of the The results of the The results of the The results of the The results of the The results of the The results of the clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis clinical pathology analysis were used were used were usedwere used were used to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment to evaluate the degree of functional impairment the organs affected by t the organs affected by t the organs affected by t the organs affected by t the organs affected by tthe organs affected by tthe organs affected by tthe organs affected by tthe organs affected by tthe organs affected by t the organs affected by tthe organs affected by tthe organs affected by tthe organs affected by the disease in dogs. he disease in dogs.he disease in dogs. he disease in dogs. he disease in dogs.he disease in dogs. he disease in dogs. he disease in dogs. The The concentrationsconcentrations concentrationsconcentrations concentrationsconcentrations concentrations of allopurinol and of allopurinol and of allopurinol and of allopurinol and of allopurinol and of allopurinol and of allopurinol and oxypurinol were oxypurinol were oxypurinol were oxypurinol were oxypurinol were oxypurinol were determindetermindetermin determin determined ed by HPLCby HPLCby HPLCby HPLC by HPLCby HPLC with UV reading with UV readingwith UV reading with UV readingwith UV readingwith UV reading with UV reading technique. The pharmacokinetic technique. The pharmacokinetic technique. The pharmacokinetic technique. The pharmacokinetic technique. The pharmacokinetic technique. The pharmacokinetic technique. The pharmacokinetic technique. The pharmacokinetic technique. The pharmacokinetic technique. The pharmacokinetic parameters found for allopurinol parameters found for allopurinol parameters found for allopurinol parameters found for allopurinol parameters found for allopurinol parameters found for allopurinol parameters found for allopurinol parameters found for allopurinol parameters found for allopurinol parameters found for allopurinol were were were were Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 Cmax of 6.00 ± 1.78 μg/mL, Tmax 1.50 0.67 h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per h, Kel of 0.31 ± 0.17 per and and Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The Vd/F/kg of 1.37 ± 0.83 L/Kg. The clearanceclearance clearance clearance interval interval interval interval interval interval (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, (Cl) was 0.35 ± 0.11 L/h/kg, and the area under curve (AUC)and the area under curve (AUC) and the area under curve (AUC) and the area under curve (AUC)and the area under curve (AUC)and the area under curve (AUC)and the area under curve (AUC)and the area under curve (AUC)and the area under curve (AUC)and the area under curve (AUC) and the area under curve (AUC) and the area under curve (AUC) and the area under curve (AUC)and the area under curve (AUC) and the area under curve (AUC)and the area under curve (AUC)and the area under curve (AUC) and the area under curve (AUC) was 27.20 ± 7.80 was 27.20 ± 7.80 was 27.20 ± 7.80 was 27.20 ± 7.80 was 27.20 ± 7.80 h*μg/mL. h*μg/mL. h*μg/mL. h*μg/mL. h*μg/mL. The values f The values fThe values fThe values f The values f The values for oxypurinolor oxypurinol or oxypurinol or oxypurinolor oxypurinol were were were were CmaCma x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax x of 3.08 ± 0.68 μg / mL, mean Tmax 5.90 ± 3.60 h 5.90 ± 3.60 h 5.90 ± 3.60 h 5.90 ± 3.60 h, and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. and the area under curve of 33.87 ± 13.10 h*μg/mL. Thus, the Thus, the averageaverage average average values values of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which of the pharmacokinetic data obtained for dogs with leishmaniasis, which were mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, wwere mostly between stages I and II of the disease, w were mostly between stages I and II of the disease, close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the ere close to those described in the literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. literature for healthy dogs. We can We can We can We can We can We can conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of conclude that for dogs in mild or controlled stages of disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease, the pharmacokinetics of allopurinol behave as in healthy dogs. disease, the pharmacokinetics of allopurinol behave as in healthy dogs.disease,
pharmacokinetics;allopurinol;canine viscera
01
81
PORTUGUES
UNIVERSIDADE FEDERAL DA BAHIA
O trabalho possui divulgação autorizada

Contexto

SAÚDE ANIMAL
DOENÇAS INFECCIOSAS E PARASITÁRIAS
Metabolismo, diagnóstico e intervenção Terapêutica na Leishmaniose Canina Naturalmente Adquirida

Banca Examinadora

STELLA MARIA BARROUIN MELO
DOCENTE - PERMANENTE
Sim
Nome Categoria
JOSE EUGENIO GUIMARAES Participante Externo
ALESSANDRA ESTRELA DA SILVA LIMA Docente - PERMANENTE
STELLA MARIA BARROUIN MELO Docente - PERMANENTE
BRUNO JOSE DUMET FERNANDES Participante Externo

Financiadores

Financiador - Programa Fomento Número de Meses
CONS NAC DE DESENVOLVIMENTO CIENTIFICO E TECNOLOGICO - CAPES 24

Vínculo

CLT
Empresa Privada
Profissional Autônomo
Não